Histopathologists, Malignancies, and Undefined High-Power Fields

Sadler, Dean; Coghill, S. B.

doi:10.1016/s0140-6736(89)92605-6

Cited by 31 publications

(18 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18), or mitotic index (r = 0.44, P= 0.23) in cases of tumours of uncertain malignant potential.Ploidy and S phase fraction Satisfactory histograms were obtained in 22/2 3 leiomyosarcomas and nine of 10 tumours of uncertain malignant potential. Aneuploidy was present in 15 in one tumour of uncertain malignant potential.…”

mentioning

confidence: 98%

Proliferation, ploidy and prognosis in uterine smooth muscle tumours

et al. 1996

View full text Add to dashboard Cite

DNA ploidy, mitotic rate (per 10 high power fields), mitotic index (per 1000 tumour nuclei), Ki-67 labelling index and S phase fraction were measured in 23 uterine leiomyosarcomas and 10 tumours of uncertain malignant potential. Correlations were calculated by Spearmann rank correlation. Univariate survival analysis was performed by log rank analysis and multivariate analysis performed by the Cox linear regression method. Ki-67 index and S phase fraction were significantly higher in leiomyosarcomas than in tumours of uncertain malignant potential. There was significant correlation between mitotic rate, mitotic index, Ki-67 index and S phase fraction in cases of leiomyosarcoma. Fifteen of 22 leiomyosarcomas and one of 10 tumours of uncertain malignant potential were DNA aneuploid. On univariate analysis of all the smooth muscle tumours, DNA ploidy, presence of significant nuclear atypia and presence of coagulative tumour cell necrosis were associated with outcome. Only DNA ploidy was associated with outcome in the group of leiomyosarcomas. On multivariate analysis of all of the smooth muscle tumours, DNA ploidy, age and grade of atypia were independently associated with outcome. No single factor was independently predictive of outcome in the group of leiomyosarcomas. Alternative indices of cell proliferation correlate with mitotic rate in uterine leiomyosarcoma and do not provide additional useful prognostic information. DNA ploidy, age and grade of atypia are independently associated with outcome in uterine smooth muscle tumours and measurement of DNA ploidy may be useful in identification of cases with an adverse prognosis.

show abstract

mentioning

confidence: 98%

Proliferation, ploidy and prognosis in uterine smooth muscle tumours

et al. 1996

View full text Add to dashboard Cite

show abstract

“…The latter change is a problem for the high‐power field (HPF). This is all too often an undefined area, and although it has served pathologists well, it varies between microscopes by up to ×4, even at the same magnification (×400), leading to many disagreements concerning the malignancy of a given tumour . Digital pathology fields are rectangular, not round, and also vary in size, so a decision to move to mitoses per mm 2 was made in February 2018 by the WHO classification of tumours editorial board.…”

Section: Changes In the 5th Editionmentioning

confidence: 99%

Revising the WHO classification: female genital tract tumours

et al. 2019

View full text Add to dashboard Cite

The upcoming revision of the World Health Organisation (WHO) classification of tumours of the female genital tract is scheduled for release in the second quarter of 2020. It will feature significant changes compared to earlier editions. In this review, we outline the process of revising this important reference source for those diagnosing tumours or engaged in cancer research and describe the significant changes. The WHO classification of tumours is increasingly evidence‐based, with a clear update cycle, improved quality of illustrations and content, led by an editorial board comprised mainly of pathologists, but increasingly incorporating input from other disciplines. The advent of the new website allows the use of whole‐slide images and hyperlinks to evidence or external bodies that produce guidance on staging or reporting.

show abstract

“…Although several methods have been used to determine the tumor proliferative fraction in the research setting, the only practical methods used in the pathology laboratory were Ki-67 and mitotic count (2). Mitotic count was long used by surgical pathologists as diagnostic and prognostic criteria in malignant tumors, but is subjective, has poor reproducibility and is dependent on laboratory techniques (3)(4)(5).…”

Section: Ki-67 As a Proliferative Markermentioning

confidence: 99%

Ki-67 expression in pulmonary tumors

Chirieac

2016

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Histopathologists, Malignancies, and Undefined High-Power Fields

Cited by 31 publications

References 2 publications

Proliferation, ploidy and prognosis in uterine smooth muscle tumours

Proliferation, ploidy and prognosis in uterine smooth muscle tumours

Revising the WHO classification: female genital tract tumours

Ki-67 expression in pulmonary tumors

Contact Info

Product

Resources

About